PT-141 (Bremelanotide), 10mg

Product Category

Melanocortin Receptor Agonists & Central Libido Modulators

Action on the Human Body

PT-141 (Bremelanotide) is a synthetic peptide analog of alpha-Melanocyte Stimulating Hormone ($alpha$-MSH), specifically representing a active cyclic metabolite fragment of Melanotan II. Unlike classical phosphodiesterase-5 inhibitors (PDE-5i) which act locally on peripheral cardiovascular dynamics, Bremelanotide targets the central nervous system by acting as a high-affinity agonist at central melanocortin receptors MC3 and MC4. Binding within the medial preoptic area of the hypothalamus triggers downward dopaminergic signaling cascades that directly activate native sexual arousal and desire loops. It drives robust autonomic cavernous nerve activation to optimize erectile rigidity and pelvic blood flow dynamics while restoring psychological libido indices in both male and female biological profiles.

What to Expect if Consumed

Users report a significant and prolonged surge in natural sexual desire, heightened pelvic sensitivity, resolution of psychological arousal deficits, and firm performance confidence starting 2 to 4 hours post-administration.

Possible Therapy Combinations

Pairs perfectly with Melanotan II for unified pigment and vitality optimization, or stacked alongside restorative longevity protocols like Epitalon to sustain background endocrine balance structures.

Molecular Formula & Chemical Composition

Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. Molecular Formula: C50H68N14O10. Purity: >99% Pure HPLC Certified Lyophilized Powder.

WARNING: This peptide compound must be handled and utilized exclusively under very high, correct professional and qualified medical supervision. Misuse can lead to unintended biological variations.

Scientific References

1. Shadiack, A. M., et al. (2004). ‘Bremelanotide (PT-141) induces sexual arousal responses via central melanocortin receptor activation.’ International Journal of Impotence Research.
2. Kingsberg, S. A., et al. (2019). ‘Bremelanotide for the treatment of hypoactive sexual desire disorder: Results from two randomized phase 3 trials.’ Obstetrics & Gynecology.